We reported previously that daily injections of isophane insulin prevented both hyperglycemia and insulitis in nonobese diabetic (NOD) mice and R. Luchetta. 1990 . . The possible mechanisms responsible include reduced immunogenicity of pancreatic fl-cells from ",B-cell rest" and induced active immunoregulation to insulin (Aaen, K., J. Rygaard, K. Josefsen, H. Petersen, C. H. Brogren, T. Horn, and K. Buschard. 1990. Diabetes. 39:697-701). We report here that intermittent immunizations with insulin or its metabolically inactive B-chain in incomplete Freund's adjuvant also prevent diabetes in NOD mice, whereas immunizations with A-chain insulin or with BSA do not. Adoptive transfer of splenocytes from B-chain insulin-immunized mice prevented diabetes in recipients co-infused with diabetogenic spleen cells, an effect that was abolished by prior in vivo elimination of either CD4+ or CD8+ cells. Insulin immunization did not reduce the extent of intraislet inflammation (insulitis); however, it did abolish expression of IFN-y mRNA within the insulitis lesions. Immunizations with insulin thus induce an active suppressive response to determinants on the B-chain that converts the insulitis lesion from one that is destructive to one that is protective. (J. Clin. Invest. 1995. 95:628-634.)
Introduction
Nonobese diabetic (NOD) ' mice regularly develop infiltrations of their pancreatic Islets of Langerhans by mononuclear leukocytes (insulitis). The lesion often progresses to an autoimmune-mediated destruction of insulin secreting /3-cells and insulindependent diabetes, especially in female mice. Although all NOD/Uf mice acquire considerable islet infiltrates, only 30% of males and 80% of females actually develop sustained hyperglycemia by 40 wk of age. The insulitis and diabetes can be transferred to irradiated recipients, indicating that an active autoimmune cellular response is involved. Prior eradication of either CD4+ or CD8+ T lymphocytes from the donor splenocytes ablates this ability to transfer diabetes. It has also been reported that immunomodulatory treatments with complete Freund's adjuvant or oral insulin can prevent or delay the onset of hyperglycemia in NOD mice without eliminating islet infiltration (1) (2) (3) . It has been proposed that such treatments alter the functional phenotypes of intraislet leukocytes, such that the insulitis lesions become "protective" rather than destructive (4) . We report here that deliberate immunization of NOD mice to insulin also induces protective insulitis lesions.
Both diabetes and insulitis can be prevented in NOD mice (5) , BB rats (6), and perhaps even in humans (7) by daily prophylactic injections of insulin. An hypothesis of "/3-cell rest" has been proposed to explain this protection, whereby the pancreatic ,/-cells enter a "quiescent" state in which expression of cellular autoantigens is reduced (8, 9) . Daily administrations of insulin to diabetic patients, however, is known to induce an active immune response characterized by insulin antibodies. We have therefore investigated whether altered immunity to insulin in NOD mice could have a role in the antidiabetic effect of prophylactic insulin therapy. Our studies indicate that an active immunization of NOD mice to an epitope on the B-chain of insulin can prevent diabetes, probably by stimulating an active immunoregulatory response that inhibits intraislet CD8+ cytotoxic T-lymphocyte effector functions.
Methods
Immunizations of insulin and its B-chain. Six units (-220 lsg) of purified porcine isophane insulin (Novo Nordisk, Copenhagen, Denmark) in incomplete Freund's adjuvant (IFA) (GIBCO, Grand Island, NY) were administered subcutaneously in the inguinal, axillary, and dorsal neck regions of weanling NOD mice (n = 12). Littermate controls received commercial hormone-free isophane insulin diluent (Novo) in IFA (n = 10). In a second study, immunizations with equivalent doses of human recombinant insulin were performed (n = 13), whereas littermate controls received injections of insulin diluent (n = 12) (12) (13) (14) .
We performed flow cytometric analyses of splenocytes from treated or control mice on a FACScan (Becton-Dickinson, San Jose, CA) after staining with GK1.5 (anti-CD4) and clone 53-6.7 (anti-CD8) antibodies (Pharmingen, San Diego, CA). Using splenocytes from B-chain immunized donors whose T cells were depleted before they were killed, adoptive cotransfers were repeated. Before transfer, six donors received treatments with anti-CD4 antibodies, eight animals were treated with anti-CD8 antibodies, and seven received injections of either PBS (n = 3) or the irrelevant IgG monoclonal antibody (n = 4).
Histology. Female NOD mice immunized to either A-chain (n = 9)
or B-chain (n = 7) insulin or treated with insulin diluent in WFA (n = 9) at 4 and 8 wk of age underwent pancreatic histological studies. They were killed at 10 wk of age (the age of established insulitis but before their onsets of diabetes), and their pancreases were removed, fixed in 10% formalin, and stained with hematoxylin and eosin for light microscopic examinations. The slides were coded and an insulitis score was determined by three independent examiners. The results were pooled and averaged before the codes were broken. The degree of insulitis was scored from 0 to 3 using a previously described dual scale that assessed both the severity of immune infiltration and the cytoarchitectural disruption (5). Cytokine production within infiltrated islets. At 4 and 8 wk of age, groups of three to four mice each received multiple subcutaneous injections of emulsions of IFA containing either insulin diluent, A-chain, or B-chain. The studies were also controlled with groups of untreated littermates. At 10 wk of age, islets from nondiabetic mice were handpicked after pancreatic mincing and collagenase/DNAse digestion. The islets were dispersed with Trypsin at 370C and the mRNA was extracted using the Micro-Fast Track mRNA Isolation Kit (InVitrogen, San Diego, CA). Cytokine-specific primers were designed as outlined previously (15) . After completing RT-PCR and agarose electrophoresis, the DNA was Southern blotted to nylon membranes (Boehringer-Mannheim, Indianapolis, IN) in 0.4 N NaOH and their identities confirmed using digoxigenin-labeled cytokine-specific internal probes and the Genius detection system (Boehringer-Mannheim). The number of islets from which message was extracted was considered as the standard for comparison between groups. The studies were performed in triplicate. The yield of DNA product using this PCR protocol has a log-linear relationship with the concentration of added template (IFN-y cDNA from Clontech, Palo Alto, CA) over at least six orders of magnitude (50 aM-50 nM). The profiles reported below were readily reproducible in replicate experiments.
Statistics. The method of Kaplan and Meier ( 16) was used to construct life tables and the logrank Chi-square statistic was used to compare them (17) . A Student's t test or one-way ANOVA was used to compare means. P values are two sided.
Results
Immunizations of insulin and its B-chain protect NOD mice from diabetes. Because the two immunization protocols yielded similar results, only the combined data are presented here. As shown in Fig. 1 , insulin immunizations dramatically lowered the incidence of diabetes over the 40-wk study period. The protection against diabetes was reproduced by immunizing with B-chain insulin but, importantly, not by immunizing with Achain insulin or with BSA as controls (latter data not presented).
The insulin immunizations stimulated active antigen-specific responses in both the humoral and the cellular arms of the immune system as expected, documenting that immunizations had not induced antigen-specific anergy. Fig. 2 A presents the frequency of anti-insulin antibody-positive mice after immunization. In all of eight insulin-immunized mice, specific antiinsulin antibodies were detected at levels that were 2 10-fold above those typical of insulin autoantibodies in untreated NOD mice in our radiobinding assay. Similarly, increases of insulin binding antibodies were also observed in sera from mice immunized against either A-or B-chain insulin. Antigen-specific proliferative responses, although modest, were also consistently stimulated as demonstrated in Fig. 2 B. Protection from diabetes can be adoptively transferred to naive recipients. To confirm the active immune basis of the therapeutic effect of B-chain insulin immunizations, 10-wk-old male irradiated recipient NOD mice were injected with splenocytes from immunized female littermates together with an equal number of splenocytes harvested from female diabetic codonors. Life table analysis revealed a significant delay in the onset of diabetes among the mice that received infusions of splenocytes from B-chain insulin-immunized donors (P < 0.007, Fig. 3 ) Among recipients of splenocytes from the untreated (n = 3), A-chain-immunized (n = 3), and diluentimmunized control groups (n = 8), 11 In B-chain insulin-immunized mice that received an in vivo course of lymphocyte-depleting antibodies before they were killed, flow cytometric analysis of splenocytes suggested virtually complete depletion of the respective T cell subsets, 3 full d after the depleting antibody course had been completed, supporting that specific T cell depletions had been affected. Both the anti-CD4 and anti-CD8 treatments reduced their respective target cell markers by 96% compared with PBS-injected control mice (Fig. 4A) . These profiles lasted for days after completing the antibody course, supporting that specific T cell depletions had been affected. Depletion of either CD4+ or CD8+ T lymphocytes before transfer abrogated the ability of B-chain-immunized splenocytes to prevent the transfer of diabetes (P < 0.01). 3 wk after the splenocyte transfer, five of six recipients depleted of CD4+ T cells and four of five recipients depleted of CD8+ T cells became hyperglycemic (Fig. 4B) . These experiments suggest that B-chain insulin immunizations inhibit islet destruction by promoting an active antigen-specific immunoregulatory lymphocyte network with suppression of islet cell autoimmunity.
Histological insulitis grade is not decreased by B-chain insulin immunization. Despite the lower frequency of diabetes seen in mice with B-chain insulin immunization, histologic studies revealed that the extent of mononuclear leukocyte infiltration of their islets was not reduced by the treatments. Using an infiltration scale of 0-3 (1), the mean and SE insulitis scores in pancreases of 10-wk-old mice immunized at 4 wk of age were 0.9±0.2, 1.3±0.3, and 1.5±0.2 for diluent (n = 9 mice), A-chain (n = 9 mice), and B-chain (n = 7 mice) treated groups, respectively (P = 0.3). The time chosen reflected an early phase of the established lesion. Further, flow cytometric analyses revealed no significant differences in the proportions of CD3+, CD4+, CD8+, or I-A+ cells in dispersed islet cell preparations from treated and control mice (data not presented).
Immunizations alter cytokine production within infiltrated islets. To assess whether functional differences existed between the islet-infiltrating immune cells of treated and control mice, cytokine mRNA profiles were examined by RT-PCR analyses (15) . The panel of cytokine-specific primers we used included IL-1,8, IL-2, IL-4, IL-10, TGF-,33, and IFN-y. The salient results are presented in Fig. 5 . High levels of IL-1O and TGF-/33 were observed in untreated mice but were not consistently increased further by insulin immunizations. Increased levels of IL-4 mRNA were observed after immunizations with IFA alone, an effect that was not seen after specific immunizations to either of the insulin peptide chains. Immunizations with either A-chain or B-chain increased intraislet levels of IL-If and 11-2 mRNA compared with controls. However, the most notable change that was specific to islet infiltrates of the highly protected B-chain insulin-immunized mice was a consistently reduced level of IFN-y mRNA.
As demonstrated by in vivo depletion of CD4+ or CD8+ cells from control unimmunized NOD mice, CD8+ cells are the predominant source of intraislet IFN-y. Cytokine mRNA levels were, however, enhanced when both T cell subsets remained (Fig. 6) . In contrast, depletion of CD4+ cells in B-chain insulin-immunized mice reduced the levels of IFN-y below the limits of detection, documenting that a reduction in CD8+ T lymphocyte transcription of IFN-y had occurred after immunizations with B-chain insulin (Fig. 6) .
Discussion
An increasing number of self-antigens targeted in autoimmune disease states have been identified at the molecular level, permitting autoantigen-based immunotherapies to become a major research focus (18) (19) (20) (21) (22) (23) (24) . To date, these antigen-based therapies have attempted to restore immunological tolerance or to otherwise induce unresponsiveness to self-antigens implicated as important in disease pathogenesis. The ability of immunization to insulin or its B-chain to prevent IDD in an antigen-specific fashion is therefore novel, because it depends on an active immune sensitization to the autoantigen and not anergy induction. Antigen specificity for the effect was demonstrated by the persistence of diabetes in NOD mice immunized with either Achain insulin or BSA in WFA and protection when immunization to B-chain was used. The induction of both humoral and in vitro cellular responses specific to the immunizing antigen documented that an active immunoregulatory process was involved and specifically ruled out the possibility that antigen-mediated immunological anergy had been induced. This hypothesis was confirmed in the adoptive cotransfer experiments, through which diabetes was prevented in naive irradiated mice receiving 630 Muir et al. (25, 26) .
Both CD4+ Th, and noncytotoxic CD8+ T-lymphocyte clones have been isolated from NOD mouse islets that can prevent diabetes when injected back into susceptible NOD recipients (27, 28) . Furthermore, similar cotransfers of spleen cells from diabetic and young nondiabetic donors result in protection from diabetes in the recipients (29) .
Immunization to A-chain insulin induced many of the same immunologic responses observed after B-chain insulin treatments, yet it did not protect against diabetes. Specific humoral and cellular responses were induced and there were parallel changes in intraislet production of IL-1, IL-2, and IL-4 using immunizations with either chain of insulin. Whereas these immunization-induced responses may in fact represent irrelevant changes, the protective CD4+/CD8+ T cell-dependent immunoregulatory network induced by B-chain insulin immunizations was associated with reduced intraislet CD8+ lymphocyte production of IFN-y. Reductions of IFN-y mRNA levels in the CD4+ T-lymphocyte population may also have been induced by immunization with insulin B-chain, but this remains unproven and is a focus for further study. Insulin is one of many /8-cell autoantigens targeted by the autoimmune response that leads to diabetes in NOD mice, but autoimmune responses against the hormone have not been considered necessary for the induction of diabetes (30) . The near complete protection from disease after therapeutic immunization with B-chain insulin is therefore consistent with the possibility that "bystander immunosuppression" has been induced. This term describes the antigen specific immunoregulatory cell release of cytokines by activated T cells, upon reencounter with the inciting antigen. The paracrine actions of such cells then down-regulate other autoreactive activated immune cells in the islet inflammatory lesion, irrespective of their cognate antigens (31) (32) (33) . The effect has been studied most in experimental allergic encephalomyelitis, induced in rodents by immunizations with myelin basic protein. The release of TGF-/3 and/ or IL-4 from myelin basic protein-specific suppressor cells is believed to ameliorate the central nervous system disease of experimental allergic encephalomyelitis by inhibiting the functions of proinflammatory cells. IL-10 is another regulatory cytokine that could have such actions; however, both beneficial and detrimental effects of IL-10 on islet viability have been described in NOD mice (34, 35) . The intraislet cytokine profiles induced by B-chain insulin immunization, however, did not demonstrate elevations of any of these cytokines, which were, however, abundant both before and after the immunizations.
Reductions of intraislet IFN-y mRNA were repeatedly demonstrated in animals who received B-chain insulin immunizations but were not observed in control mice receiving any of the nonprotective therapies. Recently, infiltrating CD8+ T lymphocytes have been reported to be the predominant source of IFN-y in NOD mouse islets (15) . In agreement with this, we found that in vivo antibody treatments that depleted CD8+ T cells of normal NOD mice reduced intraislet IFN-y mRNA more than did depletions of CD4+ T cells. Thus there was considerable transcription of IFN-y mRNA from CD8+ T cells in normal NOD mice. In contrast, islets from B-chain insulinimmunized mice demonstrated marked reductions of IFN-y transcripts and their virtual elimination was observed after subsequent anti-CD4 treatments in vivo, whereas the respective effects from anti-CD8+ treatment were much less obvious. These results indicate that B-chain insulin immunizations reduced IFN-y production at least by CD8+ T cells. We suspect that the immunization-induced process that protects islets is probably complex, and one that will require further study to unravel. 
